Liver Cirrhosis - Pipeline Review, H1 2018

  • ID: 4464917
  • Report
  • 88 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Galectin Therapeutics Inc
  • Gilead Sciences Inc
  • Novartis AG
  • Ocera Therapeutics Inc
  • Pharmicell Co Ltd
  • VESSL Therapeutics Ltd
  • MORE
Liver Cirrhosis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H1 2018, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape.

Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Liver Cirrhosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Liver Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Liver Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cirrhosis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Liver Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Liver Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Liver Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cirrhosis (Gastrointestinal)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Liver Cirrhosis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Liver Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Galectin Therapeutics Inc
  • Gilead Sciences Inc
  • Novartis AG
  • Ocera Therapeutics Inc
  • Pharmicell Co Ltd
  • VESSL Therapeutics Ltd
  • MORE
Introduction

The Publisher's Report Coverage

Liver Cirrhosis - Overview

Liver Cirrhosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Liver Cirrhosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Liver Cirrhosis - Companies Involved in Therapeutics Development

Galectin Therapeutics Inc

Gilead Sciences Inc

Human Stem Cells Institute

International Stem Cell Corp

Novartis AG

Ocera Therapeutics Inc

Pharmicell Co Ltd

Rohto Pharmaceutical Co Ltd

VESSL Therapeutics Ltd

Liver Cirrhosis - Drug Profiles

7-E - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADR-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCD-800 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Therapy for Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellgram-LC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emricasan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gemacell - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRMD-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GXHPC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ND-654 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ornithine phenylacetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide to Inhibit C/EBP-Beta for Pulmonary Fibrosis, Hepatic Injury and Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis, Pneumoconiosis and Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy to Activate ZSCAN4 for Liver Cirrhosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TLY-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Liver Cirrhosis - Dormant Projects

Liver Cirrhosis - Discontinued Products

Liver Cirrhosis - Product Development Milestones

Featured News & Press Releases

Jun 16, 2017: Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference

Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting

Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis

May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial

Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data

Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting

Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial

Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting

Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting

Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting

Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting

Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement

May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam

Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting

Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Liver Cirrhosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Liver Cirrhosis - Pipeline by Galectin Therapeutics Inc, H1 2018

Liver Cirrhosis - Pipeline by Gilead Sciences Inc, H1 2018

Liver Cirrhosis - Pipeline by Human Stem Cells Institute, H1 2018

Liver Cirrhosis - Pipeline by International Stem Cell Corp, H1 2018

Liver Cirrhosis - Pipeline by Novartis AG, H1 2018

Liver Cirrhosis - Pipeline by Ocera Therapeutics Inc, H1 2018

Liver Cirrhosis - Pipeline by Pharmicell Co Ltd, H1 2018

Liver Cirrhosis - Pipeline by Rohto Pharmaceutical Co Ltd, H1 2018

Liver Cirrhosis - Pipeline by VESSL Therapeutics Ltd, H1 2018

Liver Cirrhosis - Dormant Projects, H1 2018

Liver Cirrhosis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Liver Cirrhosis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Galectin Therapeutics Inc
  • Gilead Sciences Inc
  • Human Stem Cells Institute
  • International Stem Cell Corp
  • Novartis AG
  • Ocera Therapeutics Inc
  • Pharmicell Co Ltd
  • Rohto Pharmaceutical Co Ltd
  • VESSL Therapeutics Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll